Iberdomide Maintenance Therapy
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
What will happen during the trial?
This is a phase II study to determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle. Treatment will continue until disease progression or toxicity. A maximum of 38 participants will be enrolled. The results from this study will inform the feasibility of pursuing a phase 3 study comparing iberdomide to lenalidomide maintenance post-ASCT.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 38 patients (estimated)
- Sponsors
- University of Nebraska Medical Center
- Tags
- Cereblon E3 Ligase Modulators (CELMoDs), Maintenance
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1233
- NCT Identifier
- NCT05177536
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.